Company profile: Pulse Biosciences
1.1 - Company Overview
Company description
- Provider of medical devices using Nanosecond Pulsed Field Ablation (nsPFA), including the CellFX System for various therapeutic areas including cardiology; the CellFX nsPFA 360 Cardiac Catheter for atrial fibrillation pulmonary vein isolation; the CellFX nsPFA Cardiac Clamp for surgical cardiac ablation; and a percutaneous electrode for non-cardiac, nonthermal ablation of cellular tissue while sparing noncellular structures.
Products and services
- CellFX nsPFA 360 Cardiac Catheter: Catheter-based cardiac device employing nsPFA technology to achieve pulmonary vein isolation for atrial fibrillation treatment, engineered for targeted, nonthermal energy application
- CellFX nsPFA Cardiac Clamp: Surgical-grade device intended for cardiac ablation, offering a nonthermal mechanism to create continuous linear transmural ablations during surgical procedures
- CellFX System: Platform-grade medical device that delivers nsPFA energy for nonthermal ablation in cardiology and other therapeutic areas, targeting cellular tissue while sparing noncellular structures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pulse Biosciences
Stemcentrx
HQ: United States
Website
- Description: Provider of disease-specific cancer therapies that target tumors at their roots to cure and significantly improve survival for patients, offering pharmaceutical services. Operates as a subsidiary of AbbVie.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemcentrx company profile →
Theranostics Health
HQ: United States
Website
- Description: Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranostics Health company profile →
Paradigm
HQ: United States
Website
- Description: Provider of cutting-edge molecular diagnostics and biomarker-driven clinical trials for cancer patients and industry, using Next-Gen Sequencing and other biomarker analysis to deliver information on the genomic and proteomic landscape of a patient's cancer and potential therapies based on specific characterization of the cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paradigm company profile →
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunitas Therapeutics company profile →
BiPar Sciences
HQ: United States
Website
- Description: Provider of PARP inhibitor-based cancer therapies, developing BSI-201, an experimental PARP inhibitor in mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors; based in Brisbane, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BiPar Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pulse Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pulse Biosciences
2.2 - Growth funds investing in similar companies to Pulse Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pulse Biosciences
4.2 - Public trading comparable groups for Pulse Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →